In patients, high serum concentrations of glycodelin were associated with a decreased progression-free survival (p < 0.001) of female patients receiving an anti-PD-1 / PD-L1 therapy...In conclusion, we demonstrate that glycodelin is a protein with a high potential of being a novel target in immuno-oncology especially for NSCLC patients.